preoperative BRAF p.v600e mutation analysis as an adjunctive diagnostic and prognostic tool to routine FNA.
|
|
- Ginger Bailey
- 5 years ago
- Views:
Transcription
1 Detection of BRAF c.1799t >A (p.v600e) Mutation Using Residual Routine Fine-Needle Aspiration Specimens of Papillary Thyroid Carcinoma Huan Zhao, 1 Zhi-hui Zhang, 1 Bin Zhou, 1 Ting Xiao, 2 Qin-jing Pan, 1 and Hui-qin Guo 1 * Background: mutation is the most common genetic alteration in papillary thyroid cancer (PTC) and has been used as a diagnostic and prognostic marker in PTC. The aim of this study was to investigate the utility of preoperative mutation analysis as an adjunctive diagnostic and prognostic tool to routine fine-needle aspiration (FNA). Methods: Specimens were collected from thyroid nodules by FNA. Cytology diagnosis and testing were performed on these specimens. Molecular and cytological results were correlated with histology outcomes. Results: A total of 195 patients with thyroid nodules were enrolled, including 25 benign lesions and 170 PTCs. BRAF p.v600e testing was successfully performed in all specimens. The combination of testing and cytology improved the sensitivity of cytology from 70% to 85.3% (P ). This significant increase in sensitivity was due to the detection of PTC by testing in the nodules with atypical or suspicious PTC cytology results. Patients with -positive tumors were significantly older than those who did not harbor mutations (45.6 years vs years, P ). No correlations between mutation and other clinical-pathology parameters were observed. 1 Department of Pathology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , People s Republic of China 2 State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , People s Republic of China Contract grant sponsor: Youth Fund of Peking Union Medical College. Conflict of interest: The authors have no conflicts of interest to declare. *Correspondence to: H.-Q. Guo, Associate Prof., Department of Pathology, Cancer Institute/Hospital Chinese Academy of Medical Sciences, 17 Nanli Panjiayuan Lane, Chaoyang District, Beijing , People s Republic of China. ghqin2006@163.com Received 25 June 2014; Revised 10 April 2015; Accepted 19 June 2015 DOI: /dc Published online 7 July 2015 in Wiley Online Library (wileyonlinelibrary.com). Conclusions: Detection of mutation can be successfully carried out using residual liquid-based materials. It can be performed as a diagnostic tool to supplement traditional thyroid FNA, especially in cases with atypical or suspicious PTC. However, the role of in guidance of the extent of thyroidectomy and nodal clearance requires further study. Diagn. Cytopathol. 2015;43: VC 2015 Wiley Periodicals, Inc. Key Words: papillary thyroid carcinoma; mutation; fine-needle aspiration; diagnosis; prognosis Fine-needle aspiration (FNA) is now the most successful diagnostic test in the management of thyroid nodules. 1 3 However, FNA may also be nondiagnostic or may demonstrate indeterminate or suspicious cytologic features in 20 30% of all biopsies. 4 7 Hence, an ancillary test for suspicious FNA results is required. Moreover, the detection rate of microcarcinoma is increasing with the widespread use of ultrasound. However, the optimal management of microcarcinoma remains controversial, and often focuses on the extent of thyroidectomy and lymph node clearance. Thus, additional prognostic information provided by preoperative FNA may be helpful for surgeons in making a decision on initial treatment. BRAF c.1799t > A (p.v600e) mutation is the most common genetic alteration in papillary thyroid cancer (PTC) and is found in 15 80% of these tumors and confined to malignant nodules It is possible to speculate a diagnostic role of testing in PTC. The prognostic significance of the mutation has been explored in several studies, in which -positive PTC was found to have a more aggressive behavior. 8,11 18 In this study, we investigated the usefulness of preoperative mutation analysis as an adjunctive diagnostic and prognostic tool to routine FNA. 786 Diagnostic Cytopathology, Vol. 43, No 10 VC 2015 WILEY PERIODICALS, INC.
2 BRAF P.V600E TESTING IN THYROID FNA Materials and Methods The materials were obtained from the Cancer Institute/ Hospital, Chinese Academy of Medical Sciences (CAMS) between November 2010 and July The FNA samples were collected preoperatively and intraoperatively. Of the 195 cases, 95 samples were obtained in the outpatient clinic before surgery. The remaining 100 samples were obtained at the time of frozen examination. Intraoperative FNA biopsies were performed on surgically resected thyroid nodules by one of the two cytopathologists (Dr. Guo and Dr. Zhao). The thyroid nodules were cut in half, one half was sent for frozen pathologic diagnosis and the other half was used for FNA. FNA was performed under direct visualization. At least two passes were performed on each tumor. One pass aspirate was expressed onto a glass slide for cytologic diagnosis. The other pass was rinsed in PreservCyt solution (Hologic, Marlborough, MA, USA) for DNA extraction. FNA was repeated one or more times until suspended white particles were observed in the PreservCyt solution macroscopically. Preoperative FNA samples were retrospectively collected after obtaining clinical cytologic diagnoses. FNA biopsies were performed with one to two passes. Palpable lesions were aspirated by a cytopathologist in the FNA clinic; nonpalpable lesions using ultrasound-guided FNA were aspirated by radiologists. Aspirates were rinsed in PreservCyt solution. One ThinPrep (Hologic, Marlborough, MA, USA) slide was prepared from each case for assessment of both morphology and cellularity. Residues were collected for DNA extraction. In this way, we only selected the specimens which were diagnosed as PTC or suspicious PTC by cytology. Residue selection criteria were defined as 10 groups of cells on the slide in 10 ml of PreservCyt solution. Previous studies suggested selecting 6 10 groups of cells on the slide to perform PCR detection. 19 In order to guarantee enough DNA, our residue selection was based on both cellularity and volume. Approximately 50% of routine FNA specimens met the selection criteria and were used for molecular testing. The liquid-based materials were stored at 48C and submitted for molecular testing within 3 months. This study was reviewed and approved by the ethics committee of the Cancer Institute/Hospital, CAMS. All patients gave informed consent. Cytology Diagnosis According to the The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), cytological diagnoses were categorized as benign, atypia of indeterminate significance (AUS), follicular neoplasm (FN), suspicious malignant/suspicious papillary thyroid carcinoma (SM/ SPTC), and malignant/ptc. DNA Extraction Cells in PreservCyt solution were first centrifuged, then incubated in 500 ll of DNA lysis solution [1 mg/ml proteinase K, 10 mmol/l Tris HCl (ph 8.0), 0.1 mol/l EDTA (ph 8.0), 0.5% (w/v) SDS] at 558C for approximately 12 hours, and the DNA was then extracted by phenol and chloroform, and stored at 2208C until use. The nucleic acids were quantified using a NanoDrop spectrophotometer. Detection of BRAF P.V600E Mutation The primer sets for PCR amplification were designed as follows: (codon 600), 5 0 -TCATAATGCT TGCTCTGATAGGA-3 0 (forward), and 5 0 -GGCCAAAAA TTTAATCAGTGGA-3 0 (reverse). PCR was carried out using TaKaRa Taq DNA polymerase (TaKaRa, in a final volume of 50 ml, with 13 TaKaRa Taq Buffer with Mg 21, 200 lm of each dntp, 200 nm of forward and reverse primers, 1.25 U of TaKaRa Taq, and ng of DNA template). PCR cycling parameters were as follows: an initial denaturation at 958C for 5 min followed by 35 cycles at 958C for 30 seconds, C for 45 seconds, 728C for 30 seconds; and a final extension at 728C for 10 min. Five microliters of PCR product was run on a 1.5% agarose gel to check the specificity of amplification, and 20 ml was sent for direct sequencing with forward and reverse primers for each gene (SinoGenoMax Co., Ltd., China). Statistical Analysis The histological diagnosis in each patient was obtained from their medical records. The results of histopathology were taken as the gold standard. Cytological and molecular results were compared with histopathology. Group comparisons of categorical variables were performed using the v 2 test. The association between clinicopathologic factors and presence of the mutation was validated by the Pearson v 2 and independent t tests. Statistical analysis was carried out using SPSS 13.0 and P < 0.05 was considered statistically significant. Results A total of 195 FNA samples from 44 male and 151 female patients (mean age: 45.1 years), were included in this study. All FNA specimens were sufficient to successfully perform DNA extraction and PCR analysis. On surgical follow-up, 170 cases were confirmed as PTC, and the lesions in the other 25 cases were benign. Using cytology alone, the diagnostic sensitivity, specificity, and accuracy for the detection of PTC were 70% (119/170), 100% (25/25), and 73.8% (144/195), respectively. testing showed similar sensitivity (67.1%), specificity (100%), and accuracy (71.3%) to that Diagnostic Cytopathology, Vol. 43, No
3 ZHAO ET AL. Table I. Diagnostic Values of FNA Cytology, Testing or a Combination of Both for Detecting PTC Diagnostic modality SN (%) SP (%) PPV (%) NPV (%) AC (%) Cytology a Cytology b testing Combined a Combined b a Cytology diagnosis of malignant was taken as the diagnostic threshold. b Cytology diagnosis of suspicious malignant was taken as the diagnostic threshold. Abbreviations: SN, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; AC, accuracy. Table II. Correlation Between Cytologic Diagnoses and Mutation Status Cytologic diagnoses (n) (1) (n) (%) PTC (n 5 170) PTC SPTC FN AUS Benign Total Benign (n 5 25) SPTC FN AUS Benign Total Abbreviations: AUS, atypia of undetermined significance; FN, follicular neoplasm; SPTC, suspicious papillary thyroid carcinoma; PTC: papillary thyroid carcinoma. of cytology. When FNA cytology was combined with testing, improved sensitivity (85.3% vs 70.0%, P ) and accuracy (87.2% vs 73.8%, P ) were obtained for PTC diagnosis (Table I). Table II shows the correlation between mutations and cytological diagnoses. In terms of the two cytology categories of SPTC and AUS, testing contributed to cytology diagnosis. In the group with SPTC (n 5 41), 24 samples had mutations. At final histology, 37 were confirmed as PTC by histopathology and all mutated cases were histologically confirmed as PTC. testing confirmed 64.9% (24/37) of PTC with SPTC cytology diagnosis. In the group with AUS cytology (n 5 8), 7 were PTC. Two samples had mutations, and both were confirmed as PTC. BRAF p.v600e testing detected 28.6% (2/7) of PTC in AUS cytology samples. The clinical pathologic features of PTC according to mutation status are shown in Table III. Of 170 PTCs, 13 recurrent patients (patients who already had a diagnosis of papillary carcinoma) were excluded from this Table III. Univariate Analysis of the Association Between BRAF p.v600e Mutation and Clinicopathologic Factors Characteristic n % n % P Age at diagnosis (years) Mean 6 SD * Range Gender Male Female Capsular invasion Present Absent Extra-thyroid extension Present Absent Lymph node metastasis Present Absent Tumor size 1 cm >1 cm Multifocality Yes No AJCC stages I/II III/IV study. Of the other 157 cases, 123 were female and 34 were male aged years, with an average age of 44 years. Patients with positive tumors were significantly older than those who did not harbor the mutation (45.6 years vs years, P ). However, BRAF p.v600e mutation was not associated with patient gender, capsular invasion, extra-thyroid extension, lymph node metastasis, tumor size, multifocality, and TNM stage. In addition, no significant relationships between mutation and clinicopathologic characteristics were observed in the PTC group with tumor size 1 cm(tableiv). Discussion Positive (n 5 105) Negative (n 5 52) It has been reported that gene mutations can be successfully identified using liquid-based material with high reproducibility. 20 Therefore, it is necessary to establish criteria regarding adequate cell number for molecular testing and to avoid false-negative findings. Previous studies suggested selecting 6 10 groups of cells on the slide to perform PCR detection. 19 In order to guarantee enough DNA for analysis, we chose 10 groups of cells as the criterion in this study. With regard to the correct volume of tumor sample, most studies do not mention this. In this study, we were able to extract 300 ng to [mt]110,000 ng DNA from 10 ml of residual routine FNA specimens. This was sufficient to perform PCR detection. As this was an initial study on liquid-based residual specimens, further studies should be performed to 788 Diagnostic Cytopathology, Vol. 43, No 10
4 BRAF P.V600E TESTING IN THYROID FNA Table IV. Univariate Analysis of the Association Between BRAF p.v600e Mutation and Clinicopathologic Factors of PTCs with Tumor Size 1 cm Positive (n 5 34) Negative (n 5 16) Characteristic n % n % P Age at diagnosis (years) Mean 6 SD Range Gender Male Female Capsular invasion Present Absent 19 9 Extra-thyroid extension Present Absent Lymph node metastasis Present Absent Multifocality Yes No AJCC stages I/II III/IV 8 2 determine the smallest residual sample which can be used for molecular detection. mutation is known to be highly specific to PTC and has not been reported in follicular carcinoma, adenoma, or benign thyroid nodules. 21 Due to its high specificity, this genetic alteration is now considered a useful diagnostic marker for thyroid FNA. Zatelli et al. reported that mutation analysis increased the sensitivity of cytology for PTC from 77% to 87%. 22 Another author observed that the rate of PTC diagnosis using cytology alone was 62.3% (56/90), while the rate of PTC diagnosis using a morphomolecular method was 82.2% (74/90), with an increase of 20% in diagnostic accuracy due to mutation analysis. 23 In our study, we found that mutation testing increased the sensitivity of the FNA procedure from 70% to 85.3%. Therefore, the addition of molecular analysis resulted in an increase in sensitivity of 15.3% compared to cytology alone. Diagnostic accuracy also increased from 73.8% to 87.2%. These findings are further evidence of the efficacy of BRAF p.v600e as a diagnostic marker in thyroid FNA. In the study by Xing, the authors believed that if BRAF p.v600e testing was performed before cytology examination, nearly half of the patients with PTC did not need to undergo cytology examination, which could result in a substantial cost saving. 24 However, in clinical practice, the majority (60 80%) of FNA specimens are benign lesions and the risk of malignancy in cytology benign lesions is estimated to be <1% This means that if testing is used for screening FNA specimens, the majority of FNA specimens require an additional cytology examination. Therefore, is unsuitable as a screening tool for PTC. In this study, a significant increase in sensitivity was due to the detection of PTC by testing in nodules with suspicious FNA, which included lesions with cellular atypia and those which were suspicious malignant. In this study, testing detected 28.6% of PTC in AUS cytology samples and 64.9% of PTC in SPTC samples. Therefore, we suggest that BRAF p.v600e testing is an additional method for suspicious FNA biopsy samples. For suspicious FNA results, BRAF p.v600e mutation analysis would allow the formulation of an unambiguous surgical plan, while forgoing the need for other less specific diagnostic tests such as repeat FNA and intraoperative frozen section evaluation. The relationship between mutation and the clinicopathological outcomes of PTC has been investigated in several studies. Some authors believe that BRAF p.v600e mutation is associated with poor prognosis. 8,11 18 Li et al. conducted a meta-analysis which included 32 studies and6372patients.theyfoundthat mutation was associated with lymph node metastasis, stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic, and tall-cell variant PTC in patients with PTC. 28 However, some studies showed different results. A report from Korea indicated that the BRAF p.v600e mutation was found in 335 of 424 cases (79%) and was associated with extra-thyroidal extension and variants of PTC, and a high-risk of metastasis, patient age, local invasion, tumor size, and lymph node metastasis were not significantly associated with mutation. 29 Astudy of 214 consecutive Italian patients with classic PTC found that 41% of tumors harbored the mutation, and noted that no significant correlation with status, with the exception of patient age (52.7 years vs years). 30 These findings seem to indicate that it is unclear whether the presence of the mutation is associated with poor prognosis of PTC. In this study, mutations showed a strong association with older patients (45.6 years vs years); however, there was no relationship between BRAF p.v600e mutation and other clinicopathologic parameters including patient gender, capsular invasion, extra-thyroid extension, lymph node metastasis, tumor size, multifocality, and TNM stage. Similar results were found in our groupof50ptcswithtumorsize1 cm. Patient age was an indicator of poor prognosis in PTC. However, age is a known factor in patients waiting for a surgical decision on the extent of thyroidectomy and nodal clearance. Our results show that did not provide more information on the aggressive behavior of PTC, except in older patients. Therefore, there is no evidence to show that mutation can guide the surgical decision on the extent of thyroidectomy and nodal clearance. Diagnostic Cytopathology, Vol. 43, No
5 ZHAO ET AL. In conclusion, detection of mutation can be used successfully in liquid-based residues. mutation analysis has significant potential as a diagnostic tool to supplement traditional thyroid FNA cytology, especially in cases with atypical or suspicious PTC diagnosis. The role of in guidance of the extent of thyroidectomy and nodal clearance requires further study. Acknowledgments We thank radiologists Li-juan Niu, Yong Wang, Li Zhu, Qing Chang, and Yu Chen for their help in ultrasound guided sampling. References 1. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: A retrospective study in 37,895 patients. Cancer. 2000;90: Werga P, Wallin G, Skoog L, Hamberger B. Expanding role of fine-needle aspiration cytology in thyroid diagnosis and management. World J Surg. 2000;24: Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111: F uhrer D, M ugge C, Paschke R. Questionnaire on management of nodular thyroid disease (Annual Meeting of the Thyroid Section of the German Society of Endocrinology 2003). Exp Clin Endocrinol Diabetes. 2005;113: Filetti S, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. Nat Clin Pract Endocrinol Metab. 2006;2: Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007;36: Mazeh H, Beglaibter N, Prus D, Ariel I, Freund HR. Cytohistologic correlation of thyroid nodules. Am J Surg. 2007;194: Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28: Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94: Melck AL, Yip L, Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010;15: Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93: Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: Single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97: Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAFV600E mutation in thyroid cancer. Ann Surg. 2007; 246: Lupi C, Giannini R, Ugolini C, et al. Association of BRAFV600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92: Prescott JD, Sadow PM, Hodin RA, et al. BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012;152: Xing M, Clark D, Guan H, et al. BRAFV600E mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27: Xing M, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. Jama. 2013;309: Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146: Dyhdalo K, MacNamara S, Brainard J, et al. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples. Cancer Cytopathol. 2014;122: Rossi ED, Martini M, Capodimonti S, et al. BRAF(V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol. 2013;121: Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19: Zatelli MC, Trasforini G, Leoni S, et al. Mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 2009;161: BRAFV600E ;: Marchetti I, Lessi F, Mazzanti CM, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAFV600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009;19: Xing M. BRAFV600E mutation in thyroid cancer. Endocr Relat Cancer. 2005;12: Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations. Cancer. 2007;111: Yang GC, Liebeskind D, Messina AV. Ultrasound-guided fineneedle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: Data from 1135 biopsies with a two- to six-year follow-up. Thyroid. 2001;11: Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36: Li C, Lee KC, Schneider EB, Zeiger MA. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: A meta-analysis. J Clin Endocrinol Metab. 2012;97: Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?. Am J Surg. 2012;203: Rodolico V, Cabibi D, Pizzolanti G, et al. BRAFV600E Mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer. 2007; 110: Diagnostic Cytopathology, Vol. 43, No 10
Research Article Impact of Molecular Testing in the Diagnosis of Thyroid Fine Needle Aspiration Cytology: Data from Mainland China
Disease Markers, Article ID 912182, 6 pages http://dx.doi.org/10.1155/2014/912182 Research Article Impact of Molecular Testing in the Diagnosis of Thyroid Fine Needle Aspiration Cytology: Data from Mainland
More informationClinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease
Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease Robert L. Ferris, MD, PhD Department of Otolaryngology/Head and Neck Surgery and Yuri E. Nikiforov, MD, PhD Division of
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationUtility of BRAF mutation detection in fine-needle aspiration biopsy samples read as suspicious for papillary thyroid carcinoma
ORIGINAL ARTICLE Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as suspicious for papillary thyroid carcinoma Sebastian M. Jara, MD, 1 Ramneesh Bhatnagar, MD, 2,4 Hui
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2014 Origination: 3/2013 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More information40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016
Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital
More informationVolume 2 Issue ISSN
Volume 2 Issue 3 2012 ISSN 2250-0359 Correlation of fine needle aspiration and final histopathology in thyroid disease: a series of 702 patients managed in an endocrine surgical unit *Chandrasekaran Maharajan
More informationRepeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results
Anatomic Pathology / REPEAT THYROID FINE-NEEDLE ASPIRATION Repeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results Melina B. Flanagan, MD, MSPH, 1 N. Paul Ohori,
More informationLet s Make Sense of Present & Predict Future. In Light of Past 1/12/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationTHYROID CYTOLOGY THYROID CYTOLOGY FINE-NEEDLE-ASPIRATION ANCILLARY TESTS IN THYROID FNA
ANCILLARY TESTS IN THYROID FNA Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular Pathology Unit, IPATIMUP General-Secretary of the International
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationAPPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S.
dal 1846 APPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S. Anna Ruolo dell analisi genetica Maria Chiara Zatelli
More informationACCME/Disclosures. Questions to Myself? 4/11/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine-Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationMarkers in Thyroid Nodule Evaluation. Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center
Markers in Thyroid Nodule Evaluation Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center Disclosures Quest Diagnostics (consultant) UPMC/CBLPath
More informationDilemmas in Cytopathology and Histopathology
Dilemmas in Cytopathology and Histopathology Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center, USA Objectives Discuss new WHO classification
More informationBRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma
ORIGINAL ARTICLE BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma Jean-Franc ois Collet, MD, 1,2 Roger Lacave,
More informationRepeat Ultrasound-Guided Fine-Needle Aspiration for Thyroid Nodules 10 mm or Larger Can Be Performed 10.7 Months After Initial Nondiagnostic Results
Neuroradiology/Head and Neck Imaging Original Research Moon et al. Repeat US-Guided FNA of Thyroid Nodules After Nondiagnostic Results Neuroradiology/Head and Neck Imaging Original Research Hee Jung Moon
More informationFollicular Derived Thyroid Tumors
Follicular Derived Thyroid Tumors Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for Medical Sciences
More informationThyroid Cytopathology: Weighing In The Bethesda System
Thyroid Cytopathology: Weighing In The Bethesda System V8 Conflicts No financial consideration Bias Work in the Canadian environment where litigation is less Thyroid cytology is often referred in by small
More informationMaria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
Maria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara Molecular markers? Endocrinology
More informationThyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS Attending Pathologist Rhode Island Hospital, Providence, RI DISCLOSURE:
More informationSection 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014
Policy Number 2.04.82 Molecular Markers in Fine Needle Aspirates of the Thyroid Medical Policy Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014 Disclaimer Our medical policies
More informationMedical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: April 2014 Policy No: 49 Effective Date: July
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Markers for Fine Needle Aspirates of Thyroid Nodules MP-065-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationPredictors of Malignancy in Thyroid Fine-Needle Aspirates Cyst Fluid Only Cases
Predictors of Malignancy in Thyroid Fine-Needle Aspirates Cyst Fluid Only Cases Can Potential Clues of Malignancy Be Identified? Mohammad Jaragh, MD 1 ; V. Bessie Carydis, MMedSci (Cytol) 1 ; Christina
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationMolecular Diagnostics in Thyroid Tumors
USCAP 2011 Endocrine Pathology Society Companion Meeting Molecular Diagnostics in Thyroid Tumors Yuri E. Nikiforov, M.D., Ph.D. Department of Pathology University of Pittsburgh Medical Center Outline Overview
More informationSezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara
Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara Endocrinology Overview of genetic markers Molecular markers
More informationCase #1. Ed Stelow, MD University of Virginia
Case #1 Ed Stelow, MD University of Virginia Imagine, If You Will It s 4:30 on Friday Last cytology case A thyroid FNA from outside that did not have any onsite interpretation It is from a 45-year old
More informationTitle: Detection of BRAF Mutations on Direct Smears of Thyroid Fine Needle Aspirates through
Title: Detection of BRAF Mutations on Direct Smears of Thyroid Fine Needle Aspirates through Cell Transfer Technique Concise Title: BRAF on cell transfer cytology Qiuying Shi, MD; Ashley Ibrahim, MD; Kristi
More informationTBSRTC 1- Probabilistic approach and Relationship to Clinical Algorithms
The Benefits of a Uniform Reporting System for Thyroid Cytopathology BETHESDA REPORTING SYSTEM Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular
More informationA variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study
ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD
More informationBuilding On The Best A Review and Update on Bethesda Thyroid 2017
Building On The Best A Review and Update on Bethesda Thyroid 2017 Syed Z. Ali, MD, FRCPath, FIAC Professor of Pathology and Radiology The Johns Hopkins Hospital, Baltimore, Maryland USA TBSRTC Diagnostic
More informationSino-Dutch Biomedical and Information Engineering School, Northeastern University, Shenyang, China
Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography
More informationASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate. Thyroid Nodules: How Far Have We Come?
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate Thyroid Nodules: How Far Have We Come? William C. Faquin, MD, PhD, Massachusetts General Hospital, Boston, MA The
More informationRates of thyroid malignancy by FNA diagnostic category
Williams et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:61 ORIGINAL RESEARCH ARTICLE Open Access Rates of thyroid malignancy by diagnostic category Blair A Williams 1*, Martin J Bullock
More informationPre-operative Ultrasound of Lymph Nodes in Thyroid Cancer
Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel
More informationPEDIATRIC Ariel Katz MD
PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up
More informationA Cytohistological Correlation in Thyroid Swelling with Special Reference to The Bethesda System: A Study of 192 Cases.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 10 Ver. XI (Oct. 2017), PP 55-59 www.iosrjournals.org A Cytohistological Correlation in Thyroid
More informationImproving the Long Term Management of Benign Thyroid Nodules
25 th Annual Scientific AACE Clinical Congress Improving the Long Term Management of Benign Thyroid Nodules Stephanie L. Lee, MD, PhD Director, Thyroid Health Center Section of Endocrinology, Diabetes
More informationNIFTP Cytologic Aspects
NIFTP Cytologic Aspects William C. Faquin, MD PhD Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Boston, MA USA So, what is the story about FVPTC
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationDIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION
Follicular-patterned thyroid lesions, WC Faquin 1 DIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION William C. Faquin, M.D., Ph.D Department of Pathology, Massachusetts
More informationWork Up & Evaluation of Thyroid Nodules In 2013: State of The Art
Work Up & Evaluation of Thyroid Nodules In 2013: State of The Art BC Surgical Oncology Network, Fall Update Todd McMullen MD PhD FRCSC FACS Endocrine Surgeon Divisions of General Surgery and Oncology Director,
More informationClinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations Should Repeated FNA Be the Preferred Initial Approach?
Anatomic Pathology / Clinical Outcome for AUS Thyroid FNA Clinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations Should Repeated FNA Be the Preferred Initial Approach?
More informationThe Bethesda Indeterminate Categories: An Update to Diagnosis and Molecular Testing
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital The Bethesda Indeterminate Categories:
More informationUltrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer
Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,
More information04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy
Follicular Thyroid Tumors Updates in Classification & Practical Tips Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationOverview of Indeterminate Cytology
83 rd Annual Meeting American Thyroid Association Overview of Indeterminate Cytology Scott Boerner MD FRCPC Head Cytopathology, University Health Network University of Toronto DISCLOSURE Nothing to disclose
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationEnterprise Interest None
Enterprise Interest None Risk stratification of salivary gland lesions on cytology based on the proposed Milan System for reporting salivary gland cytopathology: A pilot study Kartik Viswanathan, M.D.,
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationThyroid Nodule Management
Thyroid Nodule Management Shane O. LeBeau, MD Clinical Associate Professor of Medicine Clinical Lead, Endocrine Thyroid Unit Division of Endocrinology, Diabetes and Metabolism University of Pittsburgh
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.78 Molecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November 26, 2014 Next
More informationDifferentiated Thyroid Carcinoma
Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University
More informationResearch Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients
yroid Research, Article ID 818134, 4 pages http://dx.doi.org/10.1155/2014/818134 Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients
More informationAACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration
AACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration Dr. Peter Singer, Endocrinology Dr. Peter Sadow, Pathology Moderator Dr. Greg Randolph, Otolaryngology Relevant Financial
More informationDynamic Risk Stratification:
Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine
More informationNeuroradiology/Head and Neck Imaging Original Research
Neuroradiology/Head and Neck Imaging Original Research Hobbs et al. FNA of Thyroid Nodules Neuroradiology/Head and Neck Imaging Original Research Hasan A. Hobbs 1 Manisha Bahl 1 Rendon C. Nelson 1,2 James
More information5/18/2013. Most thyroid nodules are benign. Thyroid nodules: new techniques in evaluation
Most thyroid nodules are benign Thyroid nodules: new techniques in evaluation Incidence Etiology Risk factors Diagnosis Gene classification system Treatment Postgraduate Course in General Surgery Jessica
More information3/27/2017. Disclosure of Relevant Financial Relationships. Each year over 550,000 thyroid FNAs are performed in the U.S.!!! THYROID FNA: THE GOOD NEWS
Disclosure of Relevant Financial Relationships William C. Faquin, MD, PhD Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital Professor of Pathology Harvard Medical
More informationDong Wook Kim, MD 1 Auh Whan Park, MD 1 Eun Joo Lee, MD 1 Hye Jung Choo, MD 1 Sang Hyo Kim, MD 2 Sang Hyub Lee, MD 2 Jae Wook Eom, MD 3
Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules Smaller Than 5 mm in the Maximum Diameter: Assessment of Efficacy and Pathological Findings Dong Wook Kim, MD 1 Auh Whan Park, MD 1 Eun
More informationThyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect
Thyroid Pathology: It starts and ends with the gross Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for
More informationMolecular Testing for Indeterminate Thyroid Nodules. October 20, 2018
Molecular Testing for Indeterminate Thyroid Nodules October 20, 2018 Patient 1: Left 1.0 cm AP x 1.6 cm transverse x 2.1 cm in length Well defined Isoechoic heterogeneous No calcification Grade 3 Vascularity
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More information"Atypical": Criteria and
"Atypical": Criteria and Controversies Esther Rossi MD PhD MIAC Division of Anatomic Pathology and Cytology Catholic University of Sacred Heart Rome, Italy CASE HISTORY In 2015, 45 y/o woman underwent
More informationNCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology
The Bethesda System For Reporting Thyroid Cytopathology Towards a Uniform Terminology With Management Guidelines NCI Thyroid FNA State of the Science Conference Bethesda, MD October 22-23, 2007 154 registrants
More informationThyroid nodules 3/22/2011. Most thyroid nodules are benign. Thyroid nodules: differential diagnosis
Most thyroid nodules are benign Thyroid nodules Postgraduate Course in General Surgery thyroid nodules occur in 77% of the world s population palpable thyroid nodules occur in about 5% of women and 1%
More informationClinical Significance of Distinguishing Between Follicular Lesion and Follicular Neoplasm in Thyroid Fine-Needle Aspiration Biopsy
Ann Surg Oncol (2009) 16:3146 3153 DOI 10.1245/s10434-009-0666-3 ORIGINAL ARTICLE ENDOCRINE TUMORS Clinical Significance of Distinguishing Between Follicular Lesion and Follicular Neoplasm in Thyroid Fine-Needle
More informationFalse-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Paek et al. World Journal of Surgical Oncology (2017) 15:202 DOI 10.1186/s12957-017-1266-5 RESEARCH Open Access False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary
More informationMolecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy
World J Surg (2010) 34:2589 2594 DOI 10.1007/s00268-010-0720-0 Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy Willieford Moses Julie Weng Ileana
More informationFNA Thyroid Cytology Structured Reporting Proforma
FNA Thyroid Cytology Structured Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth S1.02 Clinical details Male Female Intersex/indeterminate
More informationMolecular markers in thyroid cancers
Review Article DOI: 10.18203/issn.2456-3994.IntJMolImmunoOncol20172639 Molecular markers in thyroid cancers Alpa Nimesh Patel, Siddharth Singh Department of Internal Medicine, Pramukhswami Medical College,
More informationThyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary
Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with
More informationResearch Article Does Tumor Size Influence the Diagnostic Accuracy of Ultrasound-Guided Fine-Needle Aspiration Cytology for Thyroid Nodules?
International Endocrinology Volume 2016, Article ID 3803647, 6 pages http://dx.doi.org/10.1155/2016/3803647 Research Article Does Tumor Size Influence the Diagnostic Accuracy of Ultrasound-Guided Fine-Needle
More informationThyroid nodules are a common clinical presentation, with
Original Research Endocrine Surgery Thyroid Ultrasound-Guided Fine-Needle Aspiration Cytology Results: Observed Increase in Indeterminate Rate over the Past Decade Otolaryngology Head and Neck Surgery
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More informationDownloaded from by John Hanna on 11/09/15 from IP address Copyright ARRS. For personal use only; all rights reserved
Neuroradiology/Head and Neck Imaging Original Research Zhu et al. Ultrasound Versus Afirma Testing of FNA-Indeterminate Thyroid Nodules Neuroradiology/Head and Neck Imaging Original Research Qing-Li Zhu
More informationKyle C. Strickland, MD, PhD; Brooke E. Howitt, MD; Justine A. Barletta, MD; Edmund S. Cibas, MD Jeffrey F. Krane, MD, PhD
Suggesting the Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): A Retrospective Analysis of Atypical and Suspicious Nodules Kyle C. Strickland,
More informationWTC 2013 Panel Discussion: Minimal disease
WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests
More informationTitle:Number of tumor foci predicts prognosis in papillary thyroid cancer
Author's response to reviews Title:Number of tumor foci predicts prognosis in papillary thyroid cancer Authors: Qing-hai Ji (quningfudan@hotmail.com) Ning Qu (jonathan_qn@163.com) Ling Zhang (zhangling@163.com)
More informationEvaluation of thyroid isthmusectomy as a potential treatment for papillary thyroid carcinoma limited to the isthmus: A clinical study of 73 patients
ORIGINAL ARTICLE Evaluation of thyroid isthmusectomy as a potential treatment for papillary thyroid carcinoma limited to the isthmus: A clinical study of 73 patients Jianbiao Wang, MM, 1 Haili Sun, BM,
More informationUsefulness of Diagnostic Qualifiers for Thyroid Fine-Needle Aspirations With Atypia of Undetermined Significance
Anatomic Pathology / AUS Qualifiers in Thyroid FNAs Usefulness of Diagnostic Qualifiers for Thyroid Fine-Needle Aspirations With Atypia of Undetermined Significance Paul A. VanderLaan, MD, PhD, 1 Ellen
More informationWhat s an NIFTP? Keeping Up To Date in Thyroid 2018
What s an NIFTP? Keeping Up To Date in Thyroid 2018 Kathleen Hands, MD, FACE, ECNU Director, Thyroid Center of South Texas Assistant Clinical Professor UTHSCSA DrHands@Thyroid-Center.com 210-844-6163 text
More informationAn Alphabet Soup of Thyroid Neoplasms
Overall Objectives An Alphabet Soup of Thyroid Neoplasms Lester D. R. Thompson www.lester-thompson.com What is the current management of papillary carcinoma? What are the trends and what can we do differently?
More informationUpdate in Thyroid Fine Needle Aspiration
Endocr Pathol (2011) 22:178 183 DOI 10.1007/s12022-011-9182-7 Update in Thyroid Fine Needle Aspiration William C. Faquin & Massimo Bongiovanni & Peter M. Sadow Published online: 14 October 2011 # Springer
More informationA Study of Thyroid Swellings and Correlation between FNAC and Histopathology Results
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 4 (2017) pp. 265-269 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.604.030
More informationNIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli
NIFTP: Histopathology of a Cytological Monkey Wrench B. Wehrli Non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Before 2016 Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like
More informationInter-observer reproducibility using The Besthesda System for Reporting Thyroid Cytopathology (TBSRTC)
SHORT COMMUNICATION Inter-observer reproducibility in thyroid cytology reporting Inter-observer reproducibility using The Besthesda System for Reporting Thyroid Cytopathology (TBSRTC) Doshi Neena 1*, Jhabuawala
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationThe Frozen Section: Diagnostic Challenges and Pitfalls
The Frozen Section: Diagnostic Challenges and Pitfalls William C. Faquin, M.D., Ph.D. Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Harvard Medical
More informationSuspicious Cytologic Diagnostic Category in Endoscopic Ultrasound-Guided FNA of the Pancreas: Follow-Up and Outcomes
Suspicious Cytologic Diagnostic Category in Endoscopic Ultrasound-Guided FNA of the Pancreas: Follow-Up and Outcomes Evan A. Alston, MD 1 ; Sejong Bae, PhD 2 ; and Isam A. Eltoum, MD, MBA 1 BACKGROUND:
More information5/3/2017. Ahn et al N Engl J Med 2014; 371
Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult
More informationINTRODUCTION ORIGINAL ARTICLE. In Ki Hong, Jun Ho Kim 1, Young Up Cho, Shin-Young Park, Sei Joong Kim
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2016.90.4.201 Annals of Surgical Treatment and Research Clinicopathological factors increased the risk of malignancy in thyroid
More informationMedical Policy. Title: Genetic Testing- Molecular Markers in Fine Needle Aspirates (FNA) of the Thyroid
Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate
More informationMaterials and Methods
The Clinical and Diagnostic Impact of Using Standard Criteria of Adequacy Assessment and Diagnostic Terminology on Thyroid Nodule Fine Needle Aspiration Xin Jing, M.D., Claire W. Michael, M.D., and Robert
More informationCN 925/15 History. Microscopic Findings
CN 925/15 History 78 year old female. FNA indeterminate lesion right thyroid lobe. Previous THY1C (UK) Bethesda category 1 cyst fluid. Ultrasound showed part solid/cystic changes, indeterminate in nature
More informationIntroduction: Ultrasound guided Fine Needle Aspiration: When and how
International Course of Thyroid Ultrasonography and minimally invasive procedure 7-8 October 2016 University of Pisa, Italy Introduction: Ultrasound guided Fine Needle Aspiration: When and how Teresa Rago
More informationEvaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam
Overview of Thyroid Nodules and Their Management Matthew D. Ringel, M.D. Professor of Medicine Divisions of Endocrinology and Oncology, The Ohio State University Co-Director, Thyroid Cancer Unit Arthur
More information